Antibody–drug conjugates (ADCs) combine the specificity of antibodies with the potency of
small molecules to create targeted drugs. Despite the simplicity of this concept, generation of …

Antibody-drug conjugates (ADCs) are cancer therapeutic agents comprised of an antibody,
a linker and a small-molecule payload. ADCs use the specificity of the antibody to target the …

Antibody therapeutics have revolutionized the treatment of cancer over the past two
decades. Antibodies that specifically bind tumor surface antigens can be effective …

Antibody drug conjugates (ADCs) have emerged as an important pharmaceutical class of
drugs designed to harness the specificity of antibodies with the potency of small molecule …

Antibody-drug conjugates (ADCs) allow selective targeting of cytotoxic drugs to cancer cells
presenting tumor-associated surface markers, thereby minimizing systemic toxicity …

First-generation antibody–drug conjugates (ADC) are heterogeneous mixtures that have
shown clinical benefit, but generally exhibited safety issues and a narrow therapeutic …

Most chemical techniques used to produce antibody–drug conjugates (ADCs) result in a
heterogeneous mixture of species with variable drug-to-antibody ratios (DAR) which will …

The marine habitat has produced a significant number of very potent marine-derived agents
that have the potential to inhibit the growth of human tumor cells in vitro and, in a number of …

The potential of the marine environment to produce candidate compounds (structures) as
leads to, or even direct drugs from, has been actively discussed for the last 50 or so years …

It is becoming increasingly clear that site-specific conjugation offers significant advantages
over conventional conjugation chemistries used to make antibody–drug conjugates (ADCs) …